Volume 6, Issue 4 (Multidisciplinary Cancer Investigation 2022)                   Multidiscip Cancer Investig 2022, 6(4): 1-11 | Back to browse issues page

XML Print

Abstract:   (215 Views)
In 1980, tamoxifen was introduced as an effective adjuvant endocrine therapy for breast cancer, resulting in a significant increase in overall survival. Nevertheless, the development of acquired resistance limited the efficacy of tamoxifen therapy. Several molecular mechanisms have been proposed to explain the probable process of tamoxifen resistance. In vitro studies have suggested that alterations in the expression of cytoplasmic growth cascades such as insulin-like growth factor receptor (IGFR) and epidermal growth factor receptor (EGFR) along with associated downstream signaling pathways such as ERK1, ERK2, and ERK6 are the main cause of resistance to tamoxifen. In this review, we investigated the role of estrogen receptor-α (ER-α), EGFR, IGFR, and their downstream signaling pathways in tamoxifen resistance. The present study attempted to find out possible culprits of tamoxifen resistance to improve treatment efficacy in breast cancer patients.
Full-Text [PDF 395 kb]   (50 Downloads)    
Type of Study: Review Article | Subject: treatment
Received: 2022/08/1 | Accepted: 2022/10/19 | ePublished: 2022/11/5

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.